FDA grants AZ’s Imfinzi fast review in new lung cancer use
The FDA has granted AstraZeneca’s Imfinzi immunotherapy a faster six-month review in patients with extensive-stage small cell lung cancer.
AZ is asking the FDA to allow Imfinzi (durvalumab) to be used in the new indication, after previous approvals in certain patients with non-small cell lung cancer and advanced bladder cancer.
The FDA only grants priority reviews for drugs it deems to be a significant improvement on existing therapies for serious diseases.
It has set a decision date for the first quarter of 2020, setting up a potential launch next spring if the review goes AstraZeneca’s way.
FDA regulators will review a dossier of clinical data based on positive results from the phase 3 CASPIAN trial, which has already been published in The Lancet.
These results showed Imfinzi significantly improved overall survival compared with standard of care chemotherapy – etoposide with either cisplatin or carboplatin.
The risk of death was reduced by 27%, with a median overall survival of 13 months for Imfinzi plus chemotherapy compared with 10.3 months for standard of care.
Results showed an estimated 33.9% of patients were alive at 18 months following treatment with Imfinzi plus chemotherapy versus 24.7% of patients receiving standard therapy.
Around 15% of lung cancers are classified as small cell lung cancers (SCLC), and around three quarters of these patients are diagnosed with extensive-stage disease.
This is where the cancer has spread widely through the lung or to other parts of the body.
Prognosis is particularly poor as only 6% of all SCLC patients will be alive five years after diagnosis.
Imfinzi is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.
Imfinzi is well behind its main immunotherapy rivals, Merck & Co’s Keytruda and Bristol-Myers Squibb’s Opdivo, in terms of sales.
But there is still a lot more to come from Imfinzi – it is also being tested as a monotherapy and in combination with tremelimumab, an anti-CTLA4 monoclonal antibody and potential new medicine, as a treatment for patients with non-small cell lung cancer, SCLC, bladder cancer, head and neck cancer, liver cancer, biliary tract cancer, cervical cancer and other solid tumours.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.